Mirum Pharmaceuticals (NASDAQ:MIRM) Coverage Initiated at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report issued on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $48.00 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. Raymond James lowered their target price on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a strong-buy rating for the company in a research note on Tuesday, December 19th. HC Wainwright reaffirmed a buy rating and issued a $58.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, April 2nd. SVB Leerink reduced their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating for the company in a report on Monday, March 18th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. Finally, JMP Securities upped their target price on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an outperform rating in a report on Thursday, March 14th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals has an average rating of Buy and a consensus target price of $51.70.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $23.85 on Wednesday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45. The company has a fifty day simple moving average of $27.04 and a two-hundred day simple moving average of $28.56. Mirum Pharmaceuticals has a 52 week low of $23.76 and a 52 week high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). The firm had revenue of $69.55 million for the quarter, compared to analyst estimates of $66.73 million. Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. Sell-side analysts predict that Mirum Pharmaceuticals will post -1.12 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Eric Bjerkholt bought 2,000 shares of the stock in a transaction on Wednesday, March 27th. The shares were bought at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the transaction, the chief financial officer now owns 14,000 shares of the company’s stock, valued at approximately $347,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Eric Bjerkholt bought 2,000 shares of the stock in a transaction on Wednesday, March 27th. The shares were bought at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the transaction, the chief financial officer now owns 14,000 shares of the company’s stock, valued at approximately $347,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Peter Radovich sold 4,303 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $25.80, for a total transaction of $111,017.40. Following the transaction, the chief operating officer now owns 29,013 shares in the company, valued at $748,535.40. The disclosure for this sale can be found here. 24.06% of the stock is currently owned by company insiders.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. grew its position in shares of Mirum Pharmaceuticals by 98.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock valued at $31,000 after purchasing an additional 488 shares during the last quarter. AJOVista LLC acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $40,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $41,000. Royal Bank of Canada grew its position in shares of Mirum Pharmaceuticals by 40.1% in the second quarter. Royal Bank of Canada now owns 1,851 shares of the company’s stock valued at $48,000 after purchasing an additional 530 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of Mirum Pharmaceuticals by 186.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,846 shares of the company’s stock valued at $48,000 after purchasing an additional 1,202 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.